Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

181 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-13

Study Completion Date

2020-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

NCT04232280

Cytomegalovirus Infection

COMPLETED PHASE2

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

NCT05085366

Cytomegalovirus Infection

TERMINATED PHASE3

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

NCT04975893

Cytomegalovirus Infection

COMPLETED PHASE2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048

Cytomegalovirus Infection

COMPLETED PHASE1

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492

Cytomegalovirus

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytomegalovirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mRNA-1647

Group Type EXPERIMENTAL

mRNA-1647

Intervention Type BIOLOGICAL

Escalating dose levels

mRNA-1443

Group Type EXPERIMENTAL

mRNA-1443

Intervention Type BIOLOGICAL

Escalating dose levels

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mRNA-1647

Escalating dose levels

Intervention Type BIOLOGICAL

mRNA-1443

Escalating dose levels

Intervention Type BIOLOGICAL

Placebo

Saline

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Agrees to comply with the study procedures and provides written informed consent
* 18 to 49 years of age
* Body mass index between 18 and 35 kg/m2
* In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination
* Negative urine pregnancy test at the Screening visit and the day of each vaccination for females of childbearing potential
* Female subjects must either be of non-childbearing potential or use acceptable methods of contraception from at least 30 days prior to enrollment and through 3 months following last vaccination
* Male subjects must agree to practice adequate contraception for 30 days prior to the first vaccination and through 3 months following the last vaccination
* Willing to comply with the requirements of the protocol (eg, complete Diary Cards, return for follow-up visits, be available for safety phone calls)

Exclusion Criteria

* Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
* A history of malignancy in the last 10 years
* If female and of childbearing potential, is pregnant or lactating, has not adhered to an adequate contraception method from at least 30 days before study entry, or does not plan to do so for at least 3 months after the last vaccination.
* Abnormal screening safety laboratory test results including liver enzyme tests
* Administration of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine or has plans for administration during the study period
* Prior administration of investigational agent using lipid nanoparticle formulations
* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies
* A positive test result for drugs of abuse
* Chronic administration of potentially hepatotoxic drugs or have other medical conditions that affect the liver (eg, alcohol abuse)
* A history of idiopathic urticaria
* Plans for administration or has been administered a vaccine within the period from 30 days before through 30 days after each study vaccination, with the exception of any licensed influenza vaccine administered ≥15 days before or after any study vaccination
* Any chronic administration of an immunosuppressant or other immune modifying drug
* Prior administration of immunoglobulins and/or any blood products within the 3 months before the first study vaccine or has plans for administration during the study period
* Any known or suspected immune-mediated disease or immunosuppressive condition as determined by medical history and/or physical examination
* A history of hypersensitivity or serious reactions to previous vaccinations
* Any bleeding disorder considered a contraindication to IM injection or blood draw
* Any acute illness or fever at screening
* Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results
* Dose-escalation phase only, is seropositive for CMV at the Screening visit
* Donation of blood or blood products \> 450 mL within 30 days of dosing.
* Is an immediate family member or household member of study personnel
* A history of seizure disorder for which anticonvulsants are currently prescribed

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes